Further results in this study showed in vitro and in vivo that the combination of vemurafenib and erlotinib (an EGFR inhibitor) leads to a dramatic tumor response, and an improved inhibition of tumor cell proliferation [68]. The gene discussed is EGFR; the disease is neoplasm.